C6K0 Stock Overview
A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Avalo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.05 |
| 52 Week High | US$29.50 |
| 52 Week Low | US$3.62 |
| Beta | 1.03 |
| 11 Month Change | -32.96% |
| 3 Month Change | 2.84% |
| 1 Year Change | -50.06% |
| 33 Year Change | -99.83% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| C6K0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -22.6% | -0.7% | -0.02% |
| 1Y | -50.1% | -17.2% | 8.2% |
Return vs Industry: C6K0 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: C6K0 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| C6K0 volatility | |
|---|---|
| C6K0 Average Weekly Movement | 17.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: C6K0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: C6K0's weekly volatility has decreased from 38% to 18% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 19 | Garry Neil | www.avalotx.com |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases.
Avalo Therapeutics, Inc. Fundamentals Summary
| C6K0 fundamental statistics | |
|---|---|
| Market cap | €101.79m |
| Earnings (TTM) | -€7.81m |
| Revenue (TTM) | €787.45k |
129.3x
P/S Ratio-13.0x
P/E RatioIs C6K0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C6K0 income statement (TTM) | |
|---|---|
| Revenue | US$820.00k |
| Cost of Revenue | US$10.16m |
| Gross Profit | -US$9.34m |
| Other Expenses | -US$1.21m |
| Earnings | -US$8.13m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | -1,139.27% |
| Net Profit Margin | -992.07% |
| Debt/Equity Ratio | 0% |
How did C6K0 perform over the long term?
See historical performance and comparison